UNSPSC 51332877: Thioridazine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C21H26N2S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4WCI67NK8M, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)- but more generally known as thioridazine hydrochloride, which bears US NIH Compound Identifier 5452. European Medicines Agency schedules Thioridazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04821MIG.

UNSPSC 51332877 Thioridazine hydrochloride is a Commodity code that encompasses individual pharmaceutical products, though recent state and local solicitations tagged under this code show minimal activity directly tied to thioridazine itself. The code's nominal scope covers a single antipsychotic medication, but the actual procurement activity captured under it reflects broader pharmaceutical supply and distribution arrangements. State and local health authorities, including county health departments and state health and human services commissions, use related codes to procure pharmaceuticals and medical supplies through competitive bidding, cooperative purchasing vehicles, and request-for-information processes to support public health initiatives, employee health plans, and community medical programs.

Recent activity under this taxonomy includes Seminole County, Florida's IFB60459723LAS (due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. The geographic spread encompasses Florida, Texas, and the Upper Midwest. MMCAP represents a cooperative purchasing vehicle spanning multiple states with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson. The Texas and Minnesota opportunities suggest state-level demand for pharmaceutical supply chain optimization and cost management, though the code itself shows limited recent solicitation volume tied specifically to thioridazine hydrochloride.